中国医院用药评价与分析2017，Vol.17Issue(11)：1477-1480,4.DOI:10.14009/j.issn.1672-2124.2017.11.011
两种他克莫司初始治疗方案治疗特发性膜性肾病的经济学评价
Economic Evaluation on Two Primary Therapeutic Regimens of Tacrolimus in Treatment of Idiopathic Membranous Nephropathy
摘要
Abstract
OBJECTIVE:To evaluate the economical efficiency of two primary therapeutic regimens of tacrolimus in treatment of idiopathic membranous nephropathy ( IMN) , in order to obtain the best therapeutic effects with the least cost.METHODS:Pharmacoeconomics evaluation and decision tree model were adopted , 125 patients diagnosed IMN in the Affiliated Hospital of Binzhen Medical University from Nov .2014 to Jun.2016 were selected and divided into conventional administration group (68 cases) and pre-administration genetic detection group (57 cases) according to if the metabolism related genetic detection ( CYP3 A5*3 ) was conducted before the administration of tacrolimus , cost-effectiveness analysis was proceeded on the two therapeutic regimens;multi-attribute utility theory ( MAUT) was used for analyzing the effect of effective rates , therapy costs , dose adjustment times and incidences of adverse drug reactions on the selection of therapeutic regimen .RESULTS:There was no statistical significance in the effective rates between two therapeutic regimens ( P>0.05 ); the cost-effectiveness ratio of pre-administration genetic detection group was lower than that of the conventional administration group;results of MAUT analysis showed that the pre-administration genetic detection group scored higher than that of the conventional administration group .CONCLUSIONS: Results of cost-effectiveness analysis and MAUT analysis both show that the primary therapeutic regimen of pre-administration genetic detection is better than conventional administration in treatment of IMN .关键词
他克莫司/特发性膜性肾病/基因检测/CYP3A5*3/药物经济学Key words
Tacrolimus/Idiopathic membranous nephropathy/Genetic detection/CYP3A5*3/Pharmacoeconomics分类
医药卫生引用本文复制引用
马静,孙绍伟,魏传梅,窦冕,于鹏飞..两种他克莫司初始治疗方案治疗特发性膜性肾病的经济学评价[J].中国医院用药评价与分析,2017,17(11):1477-1480,4.基金项目
2014年山东省药学会临床药学奥赛康中青年科研资助项目(No.Sdpa-ask-2014-03) （No.Sdpa-ask-2014-03）
滨州医学院科研计划与科研启动基金项目( No.BY2014KJ57) （ No.BY2014KJ57）
